News

Afatinib is an oral compound targeted therapy that irreversibly inhibits both the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour

As per the terms of the license agreement, GLG Pharma has agreed to pay Moffitt when various commercialisation milestones are reached, as well as make royalty payments on

The Phase II clinical trial, coordinated by AGTC, is being conducted at The University of Massachusetts by Terrence Flotte and Cincinnati Children’s Hospital Medical Center by Bruce Trapnell.

Aricept transdermal patch NDA, if approved, is expected to be marketed by Eisai Inc, Easai’s US subsidiary, where it will co-promote the patch in collaboration with Pfizer. Easai

The new 9-minute STAT immunoassay tests include troponin T, troponin I, CK-MB, myoglobin and NT-proBNP and run on the cobas e 601 analyzer, part of the cobas 6000

Pursuant to the license agreement, TAGI Pharma is expected to market and sell four Elite generic products in the US, Puerto Rico and Canada. Elite will receive a

The launch of the trial is based on the positive GFT505-209-4 and GFT505-109-6 studies, demonstrating the insulin-sensitizing effects of GFT505 in non-diabetic subjects. International scientific coordinator of the

Cyprotex and TB Alliance aim to discover TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB

Bivium plans to introduce Cellerate RX to the Panamian health-care community at the Congress of the Panamanian Association of General Surgery conference in Panama City. The addition of